Clinical Trials · NCT06974344

Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

Not Yet RecruitingPhase 4Octreotide (Investigational)
Phase
Phase 4
Recruitment status
Not Yet Recruiting
Sponsor
King Faisal Specialist Hospital & Research Center
Enrollment
80
Start date
Jun 2025
Locations
1 site, Saudi Arabia
Primary endpoint
Median Comprehensive Complication Index® (CCI®)
View Octreotide compound reference